phone

Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2017

  • Published Date: 18 Jul 2017
  • Number of Pages: 161
  • Category: Pharmaceuticals
  • Country: Global
Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2017, provides an overview of the Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline landscape.

Hospital Acquired Pneumonia (HAP) is defined as pneumonia acquired during hospital stay. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease)
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide
The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 10, 7, 12, 1 and 1 respectively.

Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Publisher Name : Global Markets Direct

Introduction 6
Global Markets Direct Report Coverage 6
Hospital Acquired Pneumonia (HAP) - Overview 7
Hospital Acquired Pneumonia (HAP) - Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Products under Development by Companies 12
Hospital Acquired Pneumonia (HAP) - Therapeutics Assessment 16
Assessment by Target 16
Assessment by Mechanism of Action 18
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Hospital Acquired Pneumonia (HAP) - Companies Involved in Therapeutics Development 24
Achaogen Inc 24
Adenium Biotech ApS 24
Aridis Pharmaceuticals LLC 25
AstraZeneca Plc 25
Bayer AG 26
Cardeas Pharma Corp 26
Destiny Pharma Ltd 27
Dong-A Socio Holdings Co Ltd 27
Lakewood-Amedex Inc 28
MedImmune LLC 28
Meiji Seika Pharma Co Ltd 29
Melinta Therapeutics Inc 29
Merck & Co Inc 30
Motif Bio Plc 30
Nabriva Therapeutics AG 31
Polyphor Ltd 31
Sealife PHARMA GMBH 32
Shionogi & Co Ltd 32
Tetraphase Pharmaceuticals Inc 33
The Medicines Company 33
Theravance Biopharma Inc 34
Wockhardt Ltd 34
Zavante Therapeutics Inc 35
Hospital Acquired Pneumonia (HAP) - Drug Profiles 36
(amikacin sulfate + fosfomycin) - Drug Profile 36
(avibactam + ceftazidime) - Drug Profile 38
(avibactam sodium + aztreonam lysine) - Drug Profile 43
(cefepime + zidebactam) - Drug Profile 45
(ceftolozane sulfate + tazobactam sodium) - Drug Profile 46
(cilastatin sodium + imipenem + relebactam) - Drug Profile 51
(meropenem+ vaborbactam) - Drug Profile 53
AA-139 - Drug Profile 57
Aerucin - Drug Profile 58
alalevonadifloxacin - Drug Profile 60
amikacin sulfate - Drug Profile 61
arbekacin - Drug Profile 63
ASN-100 - Drug Profile 64
cefiderocol - Drug Profile 67
delafloxacin meglumine - Drug Profile 71
EBX-004 - Drug Profile 80
eravacycline - Drug Profile 81
exeporfinium chloride - Drug Profile 88
fosfomycin tromethamine - Drug Profile 90
iclaprim mesylate - Drug Profile 93
lefamulin acetate - Drug Profile 98
levonadifloxacin - Drug Profile 103
MEDI-3902 - Drug Profile 104
Mul-1867 - Drug Profile 105
murepavadin - Drug Profile 107
Nu-2 - Drug Profile 109
Nu-3 - Drug Profile 110
Panaecin - Drug Profile 112
panobacumab - Drug Profile 113
plazomicin sulfate - Drug Profile 115
POL-7001 - Drug Profile 123
Qn-2251 - Drug Profile 124
SLP-0905 - Drug Profile 125
sodium hypochlorite - Drug Profile 126
suvratoxumab - Drug Profile 127
tedizolid phosphate - Drug Profile 128
telavancin hydrochloride - Drug Profile 136
tosatoxumab - Drug Profile 141
Viritron VDX - Drug Profile 143
Hospital Acquired Pneumonia (HAP) - Dormant Projects 144
Hospital Acquired Pneumonia (HAP) - Discontinued Products 145
Hospital Acquired Pneumonia (HAP) - Product Development Milestones 146
Featured News & Press Releases 146
Appendix 157
Methodology 157
Coverage 157
Secondary Research 157
Primary Research 157
Expert Panel Validation 157
Contact Us 157
Disclaimer 158

List Of Tables


Number of Products under Development for Hospital Acquired Pneumonia (HAP), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Achaogen Inc, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Adenium Biotech ApS, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Aridis Pharmaceuticals LLC, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by AstraZeneca Plc, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Bayer AG, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Cardeas Pharma Corp, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Destiny Pharma Ltd, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Lakewood-Amedex Inc, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by MedImmune LLC, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Meiji Seika Pharma Co Ltd, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Melinta Therapeutics Inc, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Merck & Co Inc, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Motif Bio Plc, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Nabriva Therapeutics AG, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Polyphor Ltd, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Sealife PHARMA GMBH, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Shionogi & Co Ltd, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by The Medicines Company, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Theravance Biopharma Inc, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Wockhardt Ltd, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Zavante Therapeutics Inc, H2 2017
Hospital Acquired Pneumonia (HAP) - Dormant Projects, H2 2017
Hospital Acquired Pneumonia (HAP) - Discontinued Products, H2 2017

List Of Figures


Number of Products under Development for Hospital Acquired Pneumonia (HAP), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Synopsis Timetrics Leisure & Hospitality Buildings (Construction) in Saudi Arabia: Market Analytics by Category & Cost Type to 2021 contains historic and forecast market data for the leisure & hospitality buildings

View Report

Synopsis Timetrics Leisure & Hospitality Buildings (Construction) in Nigeria: Market Analytics by Category & Cost Type to 2021 contains historic and forecast market data for the leisure & hospitality buildings category

View Report

Synopsis Timetrics Leisure & Hospitality Buildings (Construction) in Poland: Market Analytics by Category & Cost Type to 2021 contains historic and forecast market data for the leisure & hospitality buildings category

View Report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports